Accessibility Menu
Santen Pharmaceutical logo

Santen Pharmaceutical(OTC) SNPHY

Current Price$11.65
Market Cap$3.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+46%
5 Year-6%
1 Year+4%
1 Month-6%
Santen Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 11.652026-07-24
Santen Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.79%USD 13.062026-07-17
1 month-5.74%USD 12.362026-06-24
3 month+12.35%USD 10.372026-04-24
Year to date+13.12%USD 10.302025-12-31
1 year+4.26%USD 11.172025-07-24
3 year+45.89%USD 7.992023-07-25
5 year-6.02%USD 12.402021-07-23
Since inception+45.98%USD 7.982011-08-31

Santen Pharmaceutical Financials at a Glance

Market Cap

$3.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥295.63B

Net Income (TTM)

¥37.93B

EPS (TTM)

$0.75

P/E Ratio

15.49

Dividend

$0.24

Beta (Volatility)

0.27 (Low)

Price

$11.65

Volume

3,773

Open

$11.59

Previous Close

$11.65

Daily Range

$11.59 - $12.29

52-Week Range

$9.22 - $13.93

Estimated Earnings Date

May 11, 2026

SNPHY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. is a global leader in the research, development, manufacturing, and distribution of pharmaceuticals and medical devices, primarily focusing on ophthalmic conditions. Established in 1890 in Osaka, Japan, Santen has built a robust pipeline of innovative products aimed at treating various eye ailments.

Products and Services
  • Prescription medications for glaucoma and ocular hypertension
  • Over-the-counter pharmaceutical products for eye care
  • Innovative treatments for myopia and dry eye conditions
Growth Outlook
  • Strong pipeline with multiple candidates in late-stage clinical trials
  • Expansion into European and Asian markets for new therapies
  • Focus on increasing market share in ophthalmic pharmaceuticals
Financial Highlights
  • Recent quarterly revenue of 82.35 billion JPY, a significant increase
  • Net income for the latest quarter reached 15.83 billion JPY
  • Trailing twelve months (TTM) net profit margin stands at 12.81%
Santen Pharmaceutical Co., Ltd. has established itself as a key player in the healthcare sector, particularly in ophthalmology. The company’s commitment to innovation is evident in its extensive pipeline, which includes several products in advanced clinical stages. Recent financial performance indicates a positive trajectory, with substantial revenue growth and a healthy net income, reflecting effective management and operational efficiency. The company's strategic focus on expanding its market presence and enhancing its product offerings positions it well for future growth, making it an intriguing option for potential investors interested in the healthcare industry.
AI Generated • Jul 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

3,968

CEO

Takeshi Ito

Website

www.santen.co.jp

Headquarters

Osaka, OS 530-8552, JP

SNPHY Financials

Key Financial Metrics (TTM)

Gross Margin

55.20%

Operating Margin

15.50%

Net Income Margin

12.81%

Return on Equity

13.15%

Return on Capital

14.39%

Return on Assets

8.83%

Earnings Yield

6.46%

Dividend Yield

2.05%

Payout Ratio

33.84%

Stock Overview

Market Cap

$3.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

321.69M

Volume

3.77K

Avg. Volume

5.03K

Financials (TTM)

Gross Profit

¥165.41B

Operating Income

¥45.94B

EBITDA

¥65.30B

Operating Cash Flow

¥36.91B

Capital Expenditure

-¥5.06B

Free Cash Flow

¥31.85B

Cash & ST Invst.

¥81.23B

Total Debt

¥34.90B

Santen Pharmaceutical Performance Analysis

Santen Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 2,059,878,301-13.1%
20242024-03-31JPY 2,090,975,9881.5%
20252025-03-31JPY 1,967,879,818-5.9%
20262026-03-31JPY 1,935,231,038-1.7%
Santen Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-11.0%
Q22025-09-302.3%
Q32025-12-315.5%
Q42026-03-3111.0%
Santen Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY -0.29N/A
20242024-03-31JPY 0.50N/A
20252025-03-31JPY 0.6835.7%
20262026-03-31JPY 0.7611.0%
Santen Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-32.7%
Q22025-09-3038.9%
Q32025-12-313.3%
Q42026-03-3193.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

¥82.35B

+6.6%

Gross Profit

¥50.58B

+9.7%

Gross Margin

61.43%

N/A

Market Cap

$3.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$944.56K

N/A

Employees

3,968

N/A

Net Income

¥15.83B

+80.1%

EBITDA

¥22.02B

+19.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

¥81.23B

-13.6%

Total Debt

¥34.90B

+2.0%

Accounts Receivable

¥72.14B

+0.5%

Inventory

¥64.86B

+25.7%

Long Term Debt

¥31.35B

N/A

Short Term Debt

¥3.55B

+7.9%

Return on Assets

8.83%

N/A

Return on Invested Capital

13.49%

N/A

Free Cash Flow

¥19.72B

+9.8%

Operating Cash Flow

¥21.59B

+14.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MAHLYMediPal Holdings Corporation
$17.63-2.00%
HAWPFHaw Par Corporation Limited
$12.58+0.00%
BVNKFBavarian Nordic A/S
$27.69+0.00%
SHWGYShandong Weigao Group Medical Polymer Company Limited
$1.60+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About SNPHY

What is the current price of Santen Pharmaceutical?

Santen Pharmaceutical is trading at $11.65 per share.

What is the 52-week range for Santen Pharmaceutical?

Over the past 52 weeks, Santen Pharmaceutical has traded between $9.22 and $13.93.

How much debt does Santen Pharmaceutical have?

As of the most recent reporting period, Santen Pharmaceutical reported total debt of ¥218.44M.

How much cash does Santen Pharmaceutical have on hand?

Santen Pharmaceutical reported ¥508.36M in cash and cash equivalents in its most recent financial results.

What is Santen Pharmaceutical’s dividend yield?

Santen Pharmaceutical currently has a dividend yield of 2.05%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services